Challenges and progress in childhood tuberculosis
Guest edited by Professor Ben Marais (University of Sydney, Australia), this series of articles provides an overview of the global child tuberculosis burden and examines issues such as diagnosis, advances in treatment, and novel vaccination approaches. The series aims to address the needs of researchers, clinicians and other individuals who require up-to-date information on this topic.
Pneumonia is pleased to be still accepting submissions for this thematic series.
Aims and scope
Pneumonia is the only journal to focus exclusively on pneumonia. Publishing original research, case reports, reviews, commentaries and correspondence, Pneumonia provides an international forum for the exchange of knowledge by scientists and clinicians involved in studying the etiology and pathogenesis of pneumonia, as well as its diagnosis, epidemiology, treatment and prevention. The journal's scope extends to research on lung infections and diagnosis, inflammation and immunity, microbial pathogenesis and viral-bacterial interactions.
Cutting-edge research, insightful reviews and dedication to the community make Pneumonia an essential resource for clinicians, researchers, respirologists and allied professionals involved with infectious diseases.
Featured blog: Not only one leader, but many: Dr James Seddon calls for action on World TB Day
World TB Day, which falls on March 24th each year, is organised by the World Health Organisation with the aim to raise public awareness of the devastating consequences of tuberculosis (TB) and the on-going efforts to end the global TB epidemic. To mark the occasion, we have discussed TB with Dr James Seddon, who has published a highly-accessed review about drug-resistant TB and advances in the treatment of childhood TB in our journal Pneumonia.
Featured article: Predictors of pneumococcal carriage and the effect of the 13-valent pneumococcal conjugate vaccination in the Western Australian Aboriginal population
The 7-valent pneumococcal conjugate vaccine (PCV7) was introduced to prevent invasive pneumococcal disease (IPD) in Western Australian (WA) Aboriginal people in 2001. PCV13 replaced PCV7 in July 2011, covering six additional pneumococcal serotypes; however, IPD rates remained high in Aboriginal people in WA. Upper respiratory tract pneumococcal carriage can precede IPD, and PCVs alter serotype distribution. This study describes the prevalence of overall carriage and that of individual serotypes in the WA Aboriginal population before and after the introduction of PCV13, along with epidemiological risk factors for carriage.
Sign up to receive article alerts
Pneumonia is published continuously online-only. We encourage you to sign up to receive free email alerts to keep up to date with all of the latest articles by registering here.
Professor Stephen I. Pelton is Professor of Pediatrics and Epidemiology at Boston University Schools of Medicine and Public Health in Massachusetts. He is also former Director of Pediatric Infectious Diseases at Boston Medical Center (BMC) and current Coordinator of Pediatric AIDS Program. Professor Pelton is an active clinician, investigator, a member of the Boston Medical University Campus Institutional Review Board, and mentor for trainees in Pediatric Infectious Diseases. He is principal investigator for the International Maternal Pediatric Adolescent AIDS Clinical Trials program (IMPAACT) at BMC that seeks to evaluate new strategies for prevention and treatment of HIV in children and adolescents. His laboratory is focused on vaccine-preventable diseases, especially those due to Streptococcus pneumoniae and new vaccines for prevention of respiratory tract infection due to nontypeable Haemophilus influenzae. Professor Pelton’s work has led to his recognition as a leading clinical scientist in studies of the impact of pneumococcal conjugate vaccine on invasive and respiratory tract disease in children. He has been named as one of Boston’s top Pediatric Infectious Diseases physicians by Boston Magazine for the past 5 years (2012–2017).
Professor Ger Rijkers, co-Editor-in-Chief, has studied the interaction between Streptococcus pneumoniae and the human immune system for most of his professional career. Being a biologist and medical immunologist by training, and working in hospital laboratories, his focus of research has been the cellular and molecular mechanisms of the immune response during infection and following vaccination. Special attention is given to the major risk groups: the young, the old, and the immunocompromised. He has published widely in the peer-reviewed literature, has presented at a great number of international scientific and medical conferences and has supervised many PhD students in their research. Professor Rijkers joined the Laboratory of Medical Microbiology and Immunology of the St Antonius Hospital in Nieuwegein, The Netherlands in 2006. As of 2012 he has been head of the Science Department of University College Roosevelt, Middelburg, The Netherlands.
2017 Journal Metrics
67 days from submission to first decision
137 days from submission to acceptance
22 days from acceptance to publication
217 Altmetric Mentions